These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1606538)
1. Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Partin AW; Steinberg GD; Pitcock RV; Wu L; Piantadosi S; Coffey DS; Epstein JI Cancer; 1992 Jul; 70(1):161-8. PubMed ID: 1606538 [TBL] [Abstract][Full Text] [Related]
2. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. Partin AW; Walsh AC; Pitcock RV; Mohler JL; Epstein JI; Coffey DS J Urol; 1989 Nov; 142(5):1254-8. PubMed ID: 2810502 [TBL] [Abstract][Full Text] [Related]
3. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Veltri RW; Miller MC; Partin AW; Coffey DS; Epstein JI Urology; 1996 Nov; 48(5):685-91. PubMed ID: 8911509 [TBL] [Abstract][Full Text] [Related]
4. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277 [TBL] [Abstract][Full Text] [Related]
5. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716 [TBL] [Abstract][Full Text] [Related]
6. Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. Hurwitz MD; DeWeese TL; Zinreich ES; Epstein JI; Partin AW Int J Cancer; 1999 Dec; 84(6):594-7. PubMed ID: 10567904 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation. Martínez-Jabaloyas JM; Ruiz-Cerdá JL; Hernández M; Jiménez A; Jiménez-Cruz F Urology; 2002 May; 59(5):715-20. PubMed ID: 11992846 [TBL] [Abstract][Full Text] [Related]
9. Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume. Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Takeuchi H J Urol; 2000 Nov; 164(5):1587-90. PubMed ID: 11025710 [TBL] [Abstract][Full Text] [Related]
10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome. De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer]. Martínez Jabaloyas JM; Jiménez Sánchez A; Ruiz Cerdá JL; Sanz Chinesta S; Sempere A; Jiménez Cruz JF Actas Urol Esp; 2004 Apr; 28(4):298-307. PubMed ID: 15248401 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127 [TBL] [Abstract][Full Text] [Related]
15. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
16. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379 [TBL] [Abstract][Full Text] [Related]
17. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500 [TBL] [Abstract][Full Text] [Related]
18. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters? Zhang YH; Kanamaru H; Oyama N; Miwa Y; Suzuki Y; Akino H; Noriki S; Okada K Urology; 2000 Mar; 55(3):377-81. PubMed ID: 10699614 [TBL] [Abstract][Full Text] [Related]
20. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer]. Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]